Compare STRO & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRO | IROQ |
|---|---|---|
| Founded | 2003 | 1883 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 91.6M |
| IPO Year | 2018 | 2011 |
| Metric | STRO | IROQ |
|---|---|---|
| Price | $16.60 | $27.31 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $18.88 | N/A |
| AVG Volume (30 Days) | ★ 131.7K | 16.3K |
| Earning Date | 03-12-2026 | 01-26-2026 |
| Dividend Yield | N/A | ★ 1.46% |
| EPS Growth | N/A | ★ 157.16 |
| EPS | N/A | ★ 1.60 |
| Revenue | ★ $105,646,000.00 | $27,979,000.00 |
| Revenue This Year | $63.08 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.06 |
| Revenue Growth | N/A | ★ 24.68 |
| 52 Week Low | $5.23 | $23.00 |
| 52 Week High | $21.25 | $27.93 |
| Indicator | STRO | IROQ |
|---|---|---|
| Relative Strength Index (RSI) | 74.44 | 61.43 |
| Support Level | $14.08 | $27.24 |
| Resistance Level | $17.33 | $27.93 |
| Average True Range (ATR) | 1.47 | 0.20 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 89.28 | 48.12 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.